Regencell Bioscience Holdings annual operating income
2019
2020
2021
2022
2023
2024
2025
Regencell Bioscience Holdings Operating Income Growth & History (RGC)
Regencell Bioscience Holdings's operating income was −$3.8M for fiscal 2025.
View full Regencell Bioscience Holdings company overviewRegencell Bioscience Holdings annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-06-30 | −$3.8M | $966,741 | — |
| 2024 | 2024-06-30 | −$4.7M | $1.5M | — |
| 2023 | 2023-06-30 | −$6.3M | $1.3M | — |
| 2022 | 2022-06-30 | −$7.6M | −$6.2M | — |
| 2021 | 2021-06-30 | −$1.4M | −$568,991 | — |
| 2020 | 2020-06-30 | −$812,371 | −$421,381 | — |
| 2019 | 2019-06-30 | −$390,990 | — | — |
Regencell Bioscience Holdings operating income trends
Over the last five fiscal years, Regencell Bioscience Holdings's operating income decreased from −$812,371 to −$3.8M, a change of −$3.0M.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
SEC-reported operating income
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Regencell Bioscience Holdings source filings ↗